- Dual-Listed (NASDAQ, ASX)
- First-in-Human Trials
- MD Anderson JV
We’re innovating precision therapies and diagnostics to empower individuals with cancer to live longer and fuller lives.
Pioneering the Future of Radiopharmaceuticals
Radiopharm Theranostics (RAD) is a clinical-stage biotech company revolutionizing cancer care through the development of first-in-class radiopharmaceuticals.
Dual-listed on the ASX (2021) and NASDAQ (2024), we are advancing a pipeline of distinct radiopharmaceutical technologies for novel oncology targets—avoiding "me-too" targets like Prostate-Specific Membrane Antigen (PSMA), Fibroblast Activation Protein (FAP) or Somatostatin Receptor 2 (SSTR2). Our proprietary platforms span across nanobodies, antibodies, small molecules and peptides, all purposefully designed to address significant unmet needs in oncology.
Read More
What sets RAD apart? We combine disruptive science with operational excellence —including reliable supply chains and strategic collaborations such as our joint venture with MD Anderson Cancer Center.
At our core, we are driven by a singular mission: to empower individuals with cancer to live longer and fuller, better lives through precision radiotherapeutics and radiodiagnostics.
Our Isotope Suppliers
Core Pillars of Innovation
- First-in-Class Science
- Clinical-Stage Impact
- Patient-First Leadership
Breaking Ground in Radiopharmaceuticals
Track our latest clinical milestones, partnerships, and breakthroughs in precision radiopharmaceuticals.
